AMAGINE, 20120103: A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintainance Regimens of Brodalumab Compared with Placebo and Usteinumab in Subjects with Moderate to Severe Plaque Psoriasis
Aims:
Brodalumab has had successful results in phase 2 clinical trial and the continuing investigation is to show that it is superior and safe to use when compared to Placebo and Ustekinumab.
Diagnosis: Moderate to Severe Plaque Psoriasis
Principal Investigator: Stephanie Mehlis, MD
IRB Approval Number: EH12-304
Sponsor: Amgen
Contact: Interested patients should contact research coordinators Barbara Gold or Manahil Khan at 847.663.6813 or derm_ctu@northshore.org.
Open to Enrollment: Yes

12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etancercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis with Long-Term Extension Period, Protocol I1F-MC-RHBA(a)
Aims:
This study is being done to see how well ixekizumab (pronounced - ix" e kiz' ue mab) will work to help people with moderate-to-severe plaque psoriasis, and if it is safe to use. Ixekizumab is an antibody that has been created to block a protein called Interleukin (IL)-17 in the body. IL-17 is involved in defense against certain types of infections, but uncontrolled IL-17 production may be involved in certain diseases including rheumatoid arthritis and psoriasis.The primary purpose of this study is to help answer the following research questions:

  • How ixekizumab compares to placebo as treatment for your psoriasis.
  • How ixekizumab compares to etanercept as treatment for your psoriasis.

Diagnosis: Moderate to Severe Plaque Psoriasis
Principal Investigator: Stephanie Mehlis, MD
IRB Approval Number: EH11-300
Sponsor: Eli Lilly
Contact:
Interested patients should contact research coordinators Barbara Gold or Manahil Khan at 847.663.6813 or derm_ctu@northshore.org.
Open to Enrollment:
Yes

× Alternate Text